Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone44-0-17-0785-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.43 billion
Profitability
Miscellaneous
Employees35,000
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Mylan (NASDAQ:MYL) Frequently Asked Questions
What is Mylan's stock symbol?
Mylan trades on the NASDAQ under the ticker symbol "MYL."
How were Mylan's earnings last quarter?
Mylan NV (NASDAQ:MYL) issued its quarterly earnings results on Monday, July, 29th. The company reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $0.95 by $0.08. The company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.82 billion. Mylan had a net margin of 0.30% and a return on equity of 18.93%. Mylan's revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 earnings per share. View Mylan's Earnings History.
When is Mylan's next earnings date?
What guidance has Mylan issued on next quarter's earnings?
Mylan issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share (EPS) guidance of $3.80-4.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.28. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.63 billion.
What price target have analysts set for MYL?
20 equities research analysts have issued 12-month price targets for Mylan's stock. Their predictions range from $18.00 to $45.00. On average, they expect Mylan's stock price to reach $29.8158 in the next year. This suggests a possible upside of 36.2% from the stock's current price. View Analyst Price Targets for Mylan.
What is the consensus analysts' recommendation for Mylan?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan.
What are Wall Street analysts saying about Mylan stock?
Here are some recent quotes from research analysts about Mylan stock:
- 1. According to Zacks Investment Research, "Mylan received a significant boost, when the FDA approved its generic version of Advair Diskus — WixelaInhub — following a few setbacks. The biosimilars portfolio is also gaining traction with a few important approvals. However, Mylan’s generic business is experiencing a slowdown. The company proactively discontinued a number of products along with transferring some to other sites. These have led to a temporary disruption in the supply of certain products and reduced volumes in North America generic sales. The FDA approved rival Teva Pharmaceutical’s generic version of EpiPen and EpiPen Jr, which, in turn, will negatively impact sales further. Moreover, slower-than-expected uptake of generic Copaxone, even after reducing the price by more than 60%, adversely impacted sales in North America. Shares have underperformed the industry in the past six months." (4/30/2019)
- 2. Cantor Fitzgerald analysts commented, ". We are lowering our 1Q19 EPS estimate for MYL to $0.70 from $0.88. The decrease in our estimate is based on comments the company made at a conference on 3/5/19. This does not affect our investment thesis, and we are thus maintaining our Neutral rating and 12-month PT of $41." (4/1/2019)
Has Mylan been receiving favorable news coverage?
News coverage about MYL stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mylan earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Mylan.
Are investors shorting Mylan?
Mylan saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 18,177,500 shares, an increase of 7.0% from the July 31st total of 16,990,800 shares. Based on an average daily trading volume, of 7,870,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.5% of the company's stock are sold short. View Mylan's Current Options Chain.
Who are some of Mylan's key competitors?
Some companies that are related to Mylan include Vertex Pharmaceuticals (VRTX), Shiseido (SSDOY), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Array Biopharma (ARRY), Elanco Animal Health (ELAN) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of Mylan own?
Who are Mylan's key executives?
Mylan's management team includes the folowing people:
- Ms. Heather Bresch, CEO & Exec. Director (Age 50)
- Mr. Rajiv Malik, Pres & Exec. Director (Age 58)
- Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)
- Mr. Anthony Mauro, Chief Commercial Officer (Age 46)
- Mr. Daniel M. Gallagher Jr., Advisor (Age 46)
Who are Mylan's major shareholders?
Mylan's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.86%), Pzena Investment Management LLC (4.09%), Invesco Ltd. (3.30%), AQR Capital Management LLC (2.18%), Bank of New York Mellon Corp (1.55%) and Menora Mivtachim Holdings LTD. (1.25%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Melina E Higgins, Paul Campbell, Rajiv Malik, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Institutional Ownership Trends for Mylan.
Which major investors are selling Mylan stock?
MYL stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Bank of Montreal Can, Bank of New York Mellon Corp, Balyasny Asset Management LLC, Man Group plc and Toronto Dominion Bank. View Insider Buying and Selling for Mylan.
Which major investors are buying Mylan stock?
MYL stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Point72 Asset Management L.P., AQR Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Ion Asset Management Ltd., Invesco Ltd. and Crestline Management LP. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Insider Buying and Selling for Mylan.
How do I buy shares of Mylan?
Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mylan's stock price today?
One share of MYL stock can currently be purchased for approximately $21.8850.
How big of a company is Mylan?
Mylan has a market capitalization of $11.29 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe.View Additional Information About Mylan.
What is Mylan's official website?
How can I contact Mylan?
Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]
MarketBeat Community Rating for Mylan (NASDAQ MYL)
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.
